Corbion N.V. (CSNVY) Analyst/Investor Day Transcript

Group 1 - The company has successfully executed the Advance 2025 strategic plan, achieving significant transformation and operational streamlining [2] - Margin expansion was realized, increasing from 13% to 16%, alongside a strengthened balance sheet with 10 consecutive quarters of positive free cash flow [2] - The specialty food ingredient business experienced a volume/mix growth of 4%, and the previously loss-making algae omega-3 business was turned into a profitable nutrition platform [2] Group 2 - The Advance 2025 plan delivered a top line CAGR of 9% and an EBITDA growth of 8% [2] - The company divested its low-growth emulsifier business and invested in new capacity, particularly a lactic acid plant in Thailand, to drive future value [2] - The upcoming Bright 2030 strategic plan is expected to build on the achievements of Advance 2025 [3]